Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?

Journal of Clinical Medicine

Ayoub Charehbili²  Duveken B. Y. Fontein²  Judith R. Kroep¹  Gerrit-Jan Liefers²  Johannes W. R. Nortier¹ 

[1] Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands; E-Mails:;Department of Surgery, Leiden University Medical Center, Albinusdreef 2, ZA Leiden 2333, The Netherlands; E-Mails:

关键词: bisphosphonates;    zoledronic acid;    chemotherapy;    neoadjuvant;    postmenopausal;   

DOI  :  10.3390/jcm2040188

来源: mdpi

【 摘 要 】

The antitumor effect of bisphosphonates (BPs) is under increasing scrutiny. Preclinical and clinical evidence has shown that BPs might sensitize breast tumors to chemotherapy. Here, we present a review of current preclinical and clinical evidence for antitumor effects of BPs, and evaluate how BPs might play a role in neoadjuvant treatment of women with breast cancer.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.